8-K: Evoke Pharma Reports Strong Q2 Growth with GIMOTI Sales Surging

Evoke Pharma's GIMOTI nasal spray saw a 47% quarter-over-quarter and 126% year-over-year increase in net product sales, reaching a record high in prescription fills during the second quarter of 2024.

Summary

• Evoke Pharma announced its financial results for the second quarter of 2024, highlighting significant growth in GIMOTI sales.
• Net product sales for GIMOTI reached approximately $2.6 million, a 47% increase compared to the previous quarter and a 126% increase year-over-year.
• The company achieved record-high prescription fills during the quarter, with a 75% year-over-year increase and 32% growth compared to the first quarter of 2024.
• Evoke Pharma has over 2,000 cumulative prescribers for GIMOTI as of June 30, 2024.
• The net loss for the quarter was approximately $1.3 million, or $0.93 per share, compared to a net loss of $1.9 million, or $6.70 per share, in the same quarter of the previous year.
• Selling, general, and administrative expenses increased to approximately $3.7 million, up from $2.8 million in the second quarter of 2023, due to higher professional fees and marketing expenses.
• Total operating expenses for the quarter were approximately $3.8 million, compared to $2.9 million in the same period of 2023.
• As of June 30, 2024, the company had approximately $9.2 million in cash and cash equivalents.
• Evoke Pharma revised its 2024 revenue guidance to $11-12 million, down from $14 million, but still reflecting over a 100% increase from the previous year if achieved.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth and improved financial metrics. However, the revised revenue guidance and ongoing net losses temper the overall sentiment.

Positives

• GIMOTI sales are showing strong growth, with a significant increase in both quarter-over-quarter and year-over-year revenue.
• The company has achieved record-high prescription fills, indicating growing market acceptance of GIMOTI.
• The partnership with ASPN Pharmacies is yielding strong results, particularly in converting prescriptions to fills.
• Evoke Pharma is expanding access to GIMOTI by increasing its filling pharmacy network.
• The company is presenting data at medical meetings, highlighting the benefits of GIMOTI and its positive impact on healthcare resource utilization.
• The net loss per share has improved compared to the same quarter last year.
• The company has a cash runway into the second quarter of 2025.

Negatives

• The company experienced a net loss of approximately $1.3 million for the quarter.
• Selling, general, and administrative expenses increased due to higher professional fees and marketing costs.
• The 2024 revenue guidance was revised down from $14 million to $11-12 million.
• The company is dependent on the success of GIMOTI and faces risks related to its commercialization and market acceptance.
• The company is subject to risks related to supply chain constraints and inflationary pressures.

Risks

• Evoke Pharma may not achieve its revised 2024 revenue guidance due to decreased demand for GIMOTI.
• The company's ability to drive market demand for GIMOTI is subject to uncertainty.
• Evoke Pharma may need to obtain additional financing to support its operations.
• The company is dependent on third parties for the manufacture of GIMOTI.
• Inadequate efficacy or unexpected adverse side effects of GIMOTI could lead to recalls or product liability claims.
• The company faces risks related to maintaining intellectual property protection for GIMOTI.
• The company is subject to risks related to the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.

Future Outlook

Evoke Pharma believes its existing cash and cash equivalents, along with future cash flows from GIMOTI sales, will be sufficient to fund operations into the second quarter of 2025. The company has revised its 2024 revenue guidance to $11-12 million, still reflecting over a 100% increase from the previous year if achieved.

Management Comments

• Exiting the second quarter of 2024 with nearly 50% growth in revenue from the previous quarter is a testament to the effectiveness of our commercial strategy.
• This quarter, we made history by hitting record-high prescription fills while witnessing increases in all other key sales metrics.
• Our strategies to grow our prescriber and patient base are working, as the GIMOTI clinical data and their personal experience on treatment is resonating with patients and providers.
• Our current and planned strategic initiatives are poised to support continued momentum as we have only scratched the surface of the total opportunity thus far.
• Our commitment remains steadfast in amplifying and emphasizing the benefits and practical applications of GIMOTI to reach as many patients as possible and grow revenues, thus doing well by doing good.
• We remain energized by the encouraging results generated to date and look forward to building on this momentum throughout the rest of the year.

Industry Context

The announcement highlights the growing market for treatments for gastrointestinal disorders, particularly diabetic gastroparesis. Evoke Pharma's focus on GIMOTI, a nasal spray formulation of metoclopramide, positions it to address the unmet needs of patients dissatisfied with current oral therapies. The company's emphasis on healthcare resource utilization data and patient experience aligns with industry trends towards value-based care and patient-centric approaches.

Comparison to Industry Standards

• While specific competitor sales figures are not provided, the 126% year-over-year growth in GIMOTI sales is significant in the pharmaceutical industry, where growth rates are often in the single or low double digits.
• The company's focus on a nasal spray formulation of metoclopramide differentiates it from companies offering only oral or injectable options, such as generic metoclopramide manufacturers.
• The emphasis on reducing hospitalizations and emergency department visits aligns with the broader industry trend of demonstrating value and cost-effectiveness of treatments, similar to how companies like Medtronic and Boston Scientific highlight the economic benefits of their medical devices.
• The company's partnership with ASPN Pharmacies is similar to other pharmaceutical companies that use specialty pharmacies to improve access and adherence to their medications, such as AbbVie's use of specialty pharmacies for Humira.

Management Changes

Stakeholder Impact

• Shareholders will be impacted by the positive sales growth and improved financial metrics, but also by the revised revenue guidance and ongoing net losses.
• Employees may benefit from the company's growth and success.
• Patients will benefit from increased access to GIMOTI and its potential to improve their symptoms.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Evoke Pharma plans to continue its commercialization efforts for GIMOTI.
• The company will focus on expanding its prescriber and patient base.
• Evoke Pharma will continue to present data at medical meetings and webinars.
• The company will build on the momentum generated in the first half of the year.

Key Dates

Keywords

GIMOTI, Evoke Pharma, Gastroparesis, Metoclopramide, Pharmaceutical, Net Product Sales, Prescription Fills, Financial Results, Reverse Stock Split, Diabetic Gastroparesis